Status:
WITHDRAWN
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Clostridium Difficile Infection (CDI)
Eligibility:
All Genders
18+ years
Brief Summary
This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fida...
Detailed Description
This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to coll...
Eligibility Criteria
Inclusion
- ≥18 years of age
- Currently an inpatient at UPMC Presbyterian
- Diagnosed with an CDI
- Being treated with Fidaxomicin
Exclusion
- not meeting entry criteria
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04070352
Start Date
August 1 2019
End Date
May 1 2023
Last Update
May 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC
Pittsburgh, Pennsylvania, United States, 15213